Seongnam, South Korea Saturday, July 19, 2025, 12:00 Hrs [IST] ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

Investors look at many variables when deciding which stocks to buy, including a company's industry. If an industry is exhibiting high growth, stocks in that sector can gain value. It' ...

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

Prescient Therapeutics has signalled its position as one of the most advanced oncology companies on the ASX, according to ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

These capabilities illustrate the multifaceted promise of AI: speeding up scientific discovery, improving patient outcomes, ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Nasus Pharma has filed to raise $11M in an IPO of its ordinary shares, according to SEC F-1 registration. Read why my outlook ...